Drug Profile


Alternative Names: Lusefi; Luseogliflozin hydrate; TS-071; TS-71

Latest Information Update: 20 May 2017

Price : $50

At a glance

  • Originator Taisho Pharmaceutical
  • Class Antihyperglycaemics; Glucosides; Phenyl ethers; Small molecules; Sugar alcohols; Sulfides
  • Mechanism of Action Sodium-glucose transporter 2 inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes

Highest Development Phases

  • Marketed Type 2 diabetes mellitus
  • No development reported Type 1 diabetes mellitus

Most Recent Events

  • 24 Jan 2017 Taisho Toyama Pharmaceutical completes a clinical trial for Type 2 diabetes mellitus in Japan (UMIN000019072)
  • 23 Jan 2017 Taisho Toyama Pharmaceutical and Seino Internal Medicine Clinic plan a clinical trial for Type-2 diabetes mellitus in Japan (PO) (UMIN000025808)
  • 16 Jul 2016 No recent reports of development identified for phase-I development in Type-2-diabetes-mellitus in USA (PO, Tablet)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top